Antiretroviral therapy is not curative. Given the challenges in providing lifelong therapy to a
global population of more than 35 million people living with HIV, there is intense interest in …

Antiretroviral therapy can effectively block HIV-1 replication and prevent or reverse
immunodeficiency in HIV-1-infected individuals. However, viral replication resumes within …

Polymorphisms in the human leukocyte antigen (HLA) class I genes can cause the rejection
of pluripotent stem cell (PSC)-derived products in allogeneic recipients. Disruption of the …

Senescent cells accumulate in human tissues during ageing and contribute to age-related
pathologies. The mechanisms responsible for their accumulation are unclear. Here we show …

HIV infection can be effectively treated by lifelong administration of combination antiretroviral
therapy, but an effective vaccine will likely be required to end the HIV epidemic. Although the …

While inbred mice have informed most of what we know about the immune system in the
modern era, they have clear limitations with respect to their ability to be informative …

Anti-cancer drug design has been acknowledged as a complicated, expensive, time-
consuming, and challenging task. How to reduce the research costs and speed up the …

Despite widespread use of the bacille Calmette–Guérin (BCG) vaccine, tuberculosis (TB)
remains a leading cause of global mortality from a single infectious agent (Mycobacterium …

The success of checkpoint blockade therapy revolutionized cancer treatment. However, we
need to increase the fraction of responding patients and overcome acquired resistance to …

Recent efforts toward an HIV vaccine focus on inducing broadly neutralizing antibodies, but
eliciting both neutralizing antibodies (nAbs) and cellular responses may be superior. Here …